• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BD Launches New AI-enabled Solutions to Drive Connectivity Across Healthcare Settings

    10/20/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email

    FRANKLIN LAKES, N.J., Oct. 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a global leader in medical technology, introduces the BD Incada™ Connected Care Platform, a new scalable, AI-enabled, cloud-based platform that unifies BD device data into one intelligent ecosystem for the first time. The BD Incada™ Platform is available now with the launch of the next-generation BD Pyxis™ Pro Automated Medication Dispensing Solution, creating enterprise-wide visibility and connectivity that transforms data into actionable insight.  

    BD Launches New AI-enabled Solutions to Drive Connectivity Across Healthcare Settings

    "Our vision for the BD Incada™ Platform is to go beyond legacy connectivity to create meaningful connections across devices from infusion pumps to patient monitors to pharmacy robotics, and unify data from those solutions into one ecosystem, transforming data into clear, actionable insights for care teams," said Bilal Muhsin, EVP and President of BD Connected Care. "These launches represent key milestones in BD's Connected Care strategy, where we are uniquely positioned with our broad portfolio from pharmacy to bedside, to leverage game-changing technology to drive meaningful benefits for our customers."



    AI-powered analytics to drive smarter, faster decisions

    Built on Amazon Web Services' (AWS) on-demand cloud computing infrastructure, the BD Incada™ Platform leverages the latest in AI technologies, such as natural language search in analytics, and is scalable to meet the data volumes created by nearly 3 million smart connected BD devices. With Analytics in the BD Incada™ Platform, data from BD's leading medication management solutions now flows through a secure, cloud platform and enables:

    • Enterprise-wide visibility into medication inventory, which helps clinicians identify patterns and ensure medication availability, reduce medication waste and improve labor efficiency
    • The ability to ask natural language questions and receive AI-powered insights and analytics on demand
    • User-customizable dashboards that empower frontline clinical teams to act on insights quickly

    Flexible, secure storage to get the right medication to the right patient, faster

    The new BD Pyxis™ Pro Dispensing Solution delivers smarter, more secure medication storage, which enables faster access at the point of care. The first-of-its-kind flexible, stackable device configuration offers more medication storage capacity to improve medication availability from refrigerated to ambient storage. The BD Pyxis™ Pro Dispensing Solution allows hospitals and health systems to easily adapt to the evolving needs of their patient populations, with features including:

    • Expanded capacity in a similar footprint, enabling clinicians to add up to 538 multi-access or 98 secure pockets without taking more space in their medication rooms
    • Enhanced security features to improve controlled substance management and medication safety efforts
    • More efficient access, with RFID badge scanning, wireless barcode scanners and illuminated bins to streamline medication retrieval

    "For over 35 years, the BD Pyxis™ System has been the backbone of medication management across hospitals and health systems, with more than 9.8 million transactions on BD Pyxis™ devices every day," said Connor Bates, Worldwide President for Medication Management Solutions at BD. "With the enhanced secure capacity, durability and AI-powered analytics of the next-generation BD Pyxis™ Pro Dispensing Solution, we're ushering in a transformative new era for medication management."

    Together, the BD Incada™ Platform and BD Pyxis™ Pro Dispensing Solution sets a new standard for unified, data-driven healthcare operations.

    About BD

    BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiency, improve safety, and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

    Contacts:

                                                                



    Media: 

    Investors:

    Fallon McLoughlin                                                   

    Adam Reiffe

    Director, Public Relations                                         

    VP, Investor Relations

    201.258.0361                                                           

    201.847.6927

    [email protected]                                       

    [email protected]       

     

    BD (Becton, Dickinson and Company) Logo (PRNewsfoto/BD (Becton, Dickinson and Company))

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-launches-new-ai-enabled-solutions-to-drive-connectivity-across-healthcare-settings-302588426.html

    SOURCE BD (Becton, Dickinson and Company)

    Get the next $BDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDX

    DatePrice TargetRatingAnalyst
    2/10/2026$202.00Overweight
    Barclays
    2/3/2026$233.00Buy
    Citigroup
    9/25/2025$211.00Sector Perform
    RBC Capital Mkts
    5/22/2025$185.00Buy → Neutral
    Citigroup
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    5/2/2025Outperform → Mkt Perform
    Raymond James
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $BDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BD Expands Testing Capabilities to Help Clinicians Improve Diagnostic Accuracy and Efficiency

    The BD Vacutainer® Urine Complete Cup Kit preserves specimen quality, streamlines testing, and helps reduce repeat collections to support better patient careFRANKLIN LAKES, N.J., Feb. 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the launch of the BD Vacutainer® Urine Complete Cup Kit, a three-tube collection system that expands and supports broader testing capabilities from a single urine specimen. The new kit is designed to preserve sample integrity and improve workflow efficiency, while red

    2/23/26 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Lanesha Minnix Named General Counsel for BD

    FRANKLIN LAKES, N.J., Feb. 19, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Lanesha Minnix has been named executive vice president and general counsel for the company, effective March 16. Minnix will be responsible for leading the Law Group and Public Affairs at BD. She will report to Tom Polen, chairman, CEO and president of BD, and serve on the BD Executive Leadership Team.Minnix most recently served as executive vice president and chief legal officer of Walgreens Boots Alliance, where she

    2/19/26 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities

    FRANKLIN LAKES, N.J., Feb. 10, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) (the "Company" or "BD"), a leading global medical technology company, today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, the "Securities" and each a "series"). Up to an Aggregate Offer Cap of $1,600,000,000 Aggregate Purchase Priceof the Outstanding Debt Securities Listed Below and each Offer SubCap Listed Below Title of Security CUSIP Number Principal Amount Outstanding Offer SubCap Acceptance Priority Level(1) U.S. Treasury Reference Security Bloomberg Reference Page Fixed Spread Early Ten

    2/10/26 1:00:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    SEC Filings

    View All

    Becton Dickinson and Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    2/10/26 4:16:23 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Becton Dickinson and Company

    10-Q - BECTON DICKINSON & CO (0000010795) (Filer)

    2/9/26 4:19:27 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    2/9/26 4:18:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scott Bertram L sold $174,027 worth of shares (953 units at $182.61), decreasing direct ownership by 3% to 36,763 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/18/26 5:20:54 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Large owner Becton Dickinson & Co disposed of 284,771,350 shares, closing all direct ownership in the company (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Reporting)

    2/11/26 4:17:41 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    New insider Urbini Massimiliano claimed ownership of 4,133 shares (SEC Form 3)

    3 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/6/26 2:31:33 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Becton Dickinson with a new price target

    Barclays resumed coverage of Becton Dickinson with a rating of Overweight and set a new price target of $202.00

    2/10/26 7:21:54 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Citigroup resumed coverage on Becton Dickinson with a new price target

    Citigroup resumed coverage of Becton Dickinson with a rating of Buy and set a new price target of $233.00

    2/3/26 6:55:14 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    RBC Capital Mkts initiated coverage on Becton Dickinson with a new price target

    RBC Capital Mkts initiated coverage of Becton Dickinson with a rating of Sector Perform and set a new price target of $211.00

    9/25/25 8:27:46 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hayes Gregory bought $1,005,742 worth of shares (5,250 units at $191.57), increasing direct ownership by 660% to 6,046 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/11/25 4:15:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/10/25 5:03:18 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    7/23/21 4:06:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Leadership Updates

    Live Leadership Updates

    View All

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors

    FRANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025. "Robbie and Jacky will further strengthen the BD board with deep expertise in health care, technology, digital transformation and artificial intelligence, as well as finance and capital markets, all of which are core to the continued advancement of our strategy," said Tom Polen, chairman, CEO and

    11/17/25 4:30:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Expands Peripheral Artery Disease Awareness Efforts with 'Love Your Limbs' Community Screening Initiative

    FRANKLIN LAKES, N.J., Sept. 2, 2025 /PRNewswire/ -- In recognition of Peripheral Artery Disease (PAD) Awareness Month, BD (Becton, Dickinson and Company) (NYSE:BDX) is shining a spotlight on a serious yet often overlooked circulatory disorder that restricts blood flow to the limbs and is a leading cause of preventable amputations. https://loveyourlimbs.com to learn more or get involved." alt="September is Peripheral Artery Disease Awareness Month. Visit https://loveyourlimbs.com to learn more or get involved."> PAD affects more than 21 million Americans1 and more than 200 milli

    9/2/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Financials

    Live finance-specific insights

    View All

    BD Reports First Quarter Fiscal 2026 Financial Results

    Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXNNew BD revenue increased 2.5% FXNGAAP and adjusted diluted EPS of $1.34 and $2.91, respectivelyCombination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation expected to close todayCompany affirms FY26 revenue growth guidance, provides Adjusted Diluted EPS guidance for New BDFRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025. "We delivered stronger‑than‑expected first‑quarter performance which reflects our disciplined execution

    2/9/26 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26

    FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on March 31, 2026, to holders of record on March 10, 2026. The indicated annual dividend rate is $4.20 per share. The company also announced it repurchased $250 million in BD stock to date in fiscal 2026. In addition, the board has authorized the company to repurchase up to 10 million shares of BD common stock in addition to the shares that remain available under the board's previous authorizations in 2021 and 2025. The authorizations pr

    1/27/26 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business

    Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transaction MILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly voted to approve the issuance of shares of Waters common stock to shareholders of Becton, Dickinson and Company (NYSE:BDX) ("BD") in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters. 

    1/27/26 9:25:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/16/24 4:29:42 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/14/24 10:02:59 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/13/24 5:00:53 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care